Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide

D. V.P. Almeida, C. Z. de Oliveira, R. C. Mariano, F. R. Kater, M. C.L.A. Souza, V. C. Ruiz-Schutz, R. Yamamura, R. Saraiva De Carvalho, F. C. Maluf, A. K. Morgans, S. Srinivas, S. Gupta, T. Dorff, E. Y. Yu, F. A. Schutz

Research output: Contribution to journalArticle

Original languageEnglish (US)
Pages (from-to)viii279
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
StatePublished - Oct 1 2018

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Almeida, D. V. P., de Oliveira, C. Z., Mariano, R. C., Kater, F. R., Souza, M. C. L. A., Ruiz-Schutz, V. C., Yamamura, R., Saraiva De Carvalho, R., Maluf, F. C., Morgans, A. K., Srinivas, S., Gupta, S., Dorff, T., Yu, E. Y., & Schutz, F. A. (2018). Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii279. https://doi.org/10.1093/annonc/mdy284.017